CN113999284B - Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus - Google Patents
Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus Download PDFInfo
- Publication number
- CN113999284B CN113999284B CN202111413917.0A CN202111413917A CN113999284B CN 113999284 B CN113999284 B CN 113999284B CN 202111413917 A CN202111413917 A CN 202111413917A CN 113999284 B CN113999284 B CN 113999284B
- Authority
- CN
- China
- Prior art keywords
- pep
- ebov
- polypeptide
- pharmaceutically acceptable
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 100
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 99
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 98
- 241001115402 Ebolavirus Species 0.000 title claims abstract description 50
- 125000004122 cyclic group Chemical group 0.000 title claims abstract description 49
- 150000003839 salts Chemical class 0.000 title claims abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 230000000840 anti-viral effect Effects 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- 230000007502 viral entry Effects 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000009098 adjuvant therapy Methods 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 230000009545 invasion Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 21
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 208000015181 infectious disease Diseases 0.000 abstract description 17
- 125000000539 amino acid group Chemical group 0.000 abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 229910052721 tungsten Inorganic materials 0.000 abstract description 2
- 229910052720 vanadium Inorganic materials 0.000 abstract description 2
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 108090000288 Glycoproteins Proteins 0.000 description 15
- 102000003886 Glycoproteins Human genes 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 241001112090 Pseudovirus Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 13
- -1 L-form amino acid Chemical class 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241001115401 Marburgvirus Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229960003804 efavirenz Drugs 0.000 description 10
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 241001115400 Zaire ebolavirus Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000884921 Bundibugyo ebolavirus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150117028 GP gene Proteins 0.000 description 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010088535 Pep-1 peptide Proteins 0.000 description 2
- YMTMNYNEZDAGMW-RNXOBYDBSA-N Phe-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N YMTMNYNEZDAGMW-RNXOBYDBSA-N 0.000 description 2
- GRVMHFCZUIYNKQ-UFYCRDLUSA-N Phe-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GRVMHFCZUIYNKQ-UFYCRDLUSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001115394 Reston ebolavirus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241001115376 Sudan ebolavirus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241001115374 Tai Forest ebolavirus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229940090805 clavulanate Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MLBZLJCMHFCTQM-UHFFFAOYSA-N (2-methylphenyl)-diphenylphosphane Chemical compound CC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MLBZLJCMHFCTQM-UHFFFAOYSA-N 0.000 description 1
- KUYKUCMYZSQREM-WCCKRBBISA-N (2S)-2-amino-3-methylbutanoic acid pentanoic acid Chemical compound CCCCC(O)=O.CC(C)[C@H](N)C(O)=O KUYKUCMYZSQREM-WCCKRBBISA-N 0.000 description 1
- FIGBOMZADOQJTB-RZVRUWJTSA-N (2S)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@@H](CCC(N)=O)C(=O)O.CN[C@@H](CCC(N)=O)C(=O)O FIGBOMZADOQJTB-RZVRUWJTSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100080277 Caenorhabditis elegans ncr-1 gene Proteins 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 108091007403 Cholesterol transporters Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XRTISHJEPHMBJG-SRVKXCTJSA-N Cys-Asp-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XRTISHJEPHMBJG-SRVKXCTJSA-N 0.000 description 1
- AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 description 1
- DIUBVGXMXONJCF-KKUMJFAQSA-N Cys-His-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DIUBVGXMXONJCF-KKUMJFAQSA-N 0.000 description 1
- ZKAUCGZIIXXWJQ-BZSNNMDCSA-N Cys-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CS)N)O ZKAUCGZIIXXWJQ-BZSNNMDCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- 101100459404 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) npc-1 gene Proteins 0.000 description 1
- 108700018419 Niemann-Pick C1 Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WZEMSIKSCALWJZ-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO.CCO WZEMSIKSCALWJZ-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- UFCZCJYLUGMEJH-UHFFFAOYSA-N dodecanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCC(O)=O UFCZCJYLUGMEJH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- KBMLJKBBKGNETC-UHFFFAOYSA-N magnesium manganese Chemical compound [Mg].[Mn] KBMLJKBBKGNETC-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940044959 vaginal cream Drugs 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 229940098946 vaginal ointment Drugs 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cyclic polypeptide or a pharmaceutically acceptable salt thereof for resisting Ebola virus. The amino acid sequence of the cyclic polypeptide is shown in the following (formula I): x 1X2X3X4X5X6X7X8 (formula i) wherein each of X 1 to X 8 is an amino acid residue, X 1 is C, X 2 is E, D, H or Y, X 3 is Y, X 4 is F, X 5 is F, X 6 is W or V, X 7 is Y or H, and X 8 is C; x 1 in the formula I and X 8 form disulfide bond connection to form a ring. The cyclic polypeptide can specifically inhibit ebola virus from entering cells by combining with a target protein EBOV-GPcl, so as to achieve the effect of resisting EBOV infection.
Description
The application is a divisional application with the application number 2020104602227, the application number 201810087839.1 and the application date 2018, 01 and 30 of the original application, and the application and the creation name are polypeptides specifically combined with the Ebola virus activated envelope glycoprotein and application thereof in antiviral.
Technical Field
The invention relates to a cyclic polypeptide for resisting Ebola virus or a medicinal salt thereof in the technical field of medicines.
Background
Ebola virus disease (formerly known as Ebola hemorrhagic fever) is an acute hemorrhagic infectious disease caused by Ebola virus (EBOV) of the family filoviridae, and has a mortality rate of up to 90% and is one of the most fatal viral infectious diseases in humans. EBOV can be classified into 5 species, zaire type (Zaire ebolavirus, zaire-EBOV, ZEBOV), sudan type (Sudan ebolavirus, SUDV), taisen type (Tai Forest ebolavirus, TAFV), bendibu type (Bundibugyo ebolavirus, BDBV) and rice type (Reston ebolavirus, RESTV). Among them, zaire type ebola virus is the strongest in pathogenicity. At present, symptomatic and supportive treatment is mainly adopted for EBOV infection, and no specific therapeutic drug and vaccine which are effective through systematic clinical verification are available. With the increasing global population fluidity and the existence of EBOV superdiffusers in combination with the strong pathogenicity of the virus itself and the susceptibility to genetic variation, EBOV has become a potential global health threat. Therefore, it is necessary to study anti-EBOV drugs with definite targets and brand new structural types, ensuring the ability to prevent EBOV infection and cope with new outbreaks of infectious diseases.
The EBOV is a single-strand negative strand RNA virus, the outermost layer is wrapped by a virus envelope, and the center is a spiral nucleocapsid. The genome is about 18.9kb in length, encodes seven structural proteins, and has the gene sequence of 3-NP-VP35-VP40-GP-VP30-VP24-L-5. Among these, the envelope glycoprotein (glycoprotein, GP) is the only protein responsible for viral entry into host cells. GP, whether it is covered on the surface of the virus or shed from infected cells during infection, can participate in a variety of immune response reactions, playing an important role in the viral life cycle and host-pathogen interactions, and is a potentially effective target for inhibiting EBOV infection. Since the viral entry phase is the first step in the viral replication cycle, blocking EBOV-GP mediated viral entry will effectively inhibit viral infection and cytotoxicity caused thereby, while also reducing the occurrence of drug resistance. Cleavage occurs after the EBOV-GP enters lysosomes, and activated glycoprotein (Primed GP, GPcl) after cleavage can directly interact with endocytosis receptor-human cholesterol transporter (Niemann-Pick C1, NPC 1), thereby initiating the process of membrane fusion of the virus with the inside of host cells.
Disclosure of Invention
The technical problem to be solved by the invention is how to specifically inhibit ebola virus from entering cells so as to resist EBOV infection.
In order to solve the technical problems, the invention provides a cyclic polypeptide or a pharmaceutically acceptable salt thereof.
In the cyclic polypeptide or the pharmaceutically acceptable salt thereof provided by the invention, the amino acid sequence of the cyclic polypeptide is shown in the following formula (I):
x 1X2X3X4X5X6X7X8 (formula I),
In the formula I, X 1 to X 8 are each an amino acid residue, wherein X 1 is C, X 2 is E, D, H or Y, X 3 is Y, X 4 is F, X 5 is F, X 6 is W or V, X 7 is Y or H, and X 8 is C; x 1 in the formula I and X 8 form disulfide bond connection to form a ring.
In the above cyclic polypeptide or pharmaceutically acceptable salt thereof, the cyclic polypeptide may be Pep-3.3, pep-3.2, pep-3.1 or Pep-3.10; the amino acid sequence of the Pep-3.3 is SEQ ID No.1 in a sequence table, the amino acid sequence of the Pep-3.2 is SEQ ID No.2 in the sequence table, the amino acid sequence of the Pep-3.1 is SEQ ID No.3 in the sequence table, and the amino acid sequence of the Pep-3.10 is SEQ ID No.4 in the sequence table.
Derivatives of the above cyclic polypeptides are also within the scope of the present invention.
The derivative of the cyclic polypeptide may be d1, d2, d3, d4 or d5; d1 is a linker obtained by connecting an amino-terminal protecting group to the amino terminus of the cyclic polypeptide and/or connecting a carboxyl-terminal protecting group to the carboxyl terminus of the cyclic polypeptide;
D2 is a polypeptide which is obtained by adding an amino acid residue at the amino terminal end and/or the carboxyl terminal end of the cyclic polypeptide and can be specifically combined with GPcl (activated envelope glycoprotein of virus);
D3 is a polypeptide which is obtained by connecting oligopeptide at the amino terminal end and/or the carboxyl terminal end of the cyclic polypeptide and can be specifically combined with GPcl;
D4 is a modifier obtained by modifying the cyclic polypeptide by protein, polyethylene glycol or maleimide;
The d5 is a polypeptide which is obtained by connecting a lipophilic compound to the amino terminal end and/or the carboxyl terminal end of the cyclic polypeptide and can be specifically combined with GPcl.
The following multimers of PM1 or PM2 are also within the scope of the invention:
PM1, a multimer formed from the cyclic polypeptide or a pharmaceutically acceptable salt thereof;
PM2, multimers formed from said derivatives.
In the above cyclic polypeptides, pharmaceutically acceptable salts thereof, or derivatives thereof, each capital letter in the sequence of the cyclic polypeptide is an abbreviation for an amino acid, which has the meaning well known in the art, for example: c is cysteine, D is aspartic acid, E is glutamic acid, Y is tyrosine, F is phenylalanine, W is tryptophan, V is valine, H is histidine, and the like. All amino acids in the cyclic polypeptide sequence can be L-type amino acids, and one or more (such as 2-5, 2-4 or 2-3) amino acids can be replaced by amino acids with D-type conformations, artificially modified amino acids, rare amino acids existing in nature and the like so as to improve the bioavailability, stability and/or antiviral activity of the cyclic polypeptide. Wherein the D-form amino acid refers to an amino acid corresponding to the L-form amino acid constituting the protein; artificially modified amino acids refer to common L-type amino acids which are modified by methylation, phosphorylation and the like to form proteins; rare amino acids that exist in nature include unusual amino acids that constitute proteins and amino acids that do not constitute proteins, such as 5-hydroxylysine, methylhistidine, gamma-aminobutyric acid, homoserine, and the like.
In the above cyclic polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, the lipophilic compound may be attached to the side chain of the terminal amino acid or may be directly attached to the peptide chain.
In the above cyclic polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, the amino-terminal end of the cyclic polypeptide of the present invention may contain an amino-terminal protecting group, which may be any of acetyl, amino, maleyl, succinyl, t-butoxycarbonyl or benzyloxy or other hydrophobic groups or macromolecular carrier groups; the carboxyl terminal of the cyclic polypeptides of the present invention may contain a carboxyl terminal protecting group, which may be any of amino, amido, carboxyl, or t-butoxycarbonyl groups or other hydrophobic groups or macromolecular carrier groups.
Compositions comprising the following C1) and C2) are also within the scope of the invention: c1 C11), C12) or/and C13); the C11) is the above cyclic polypeptide or a pharmaceutically acceptable salt thereof; the C12) is the derivative; the C13) is the above polymer;
C2 Pharmaceutically acceptable carriers or excipients;
The composition has at least one of the following functions F1) -F3):
F1 Antiviral;
F2 Treatment and/or prevention and/or adjuvant therapy of diseases caused by viral infections;
F3 Inhibiting viral entry into the cell.
In the above composition, the viruses F1) -F3) may be Ebola virus (Zaler type, sudan type, taisenia type, bendibuch type and/or Leston type), or Marburg virus (MARV).
The use of the abovementioned C11), the abovementioned C12), the abovementioned C13) or/and C14) for preparing at least one of the products E1) to E3) also falls within the scope of the invention:
the C14) is the composition;
the E1) is an antiviral product, such as a drug or vaccine;
The E2) is a product for treating and/or preventing and/or assisting in treating diseases caused by virus infection, such as medicines or vaccines;
The E3) is a product for inhibiting the invasion of virus into cells, such as a drug or vaccine;
In the above application, the viruses E1) -E3) may be Ebola virus (Zaler type, sudan type, taisen type, bendibuch type and/or Leston type), or Marburg virus.
The present invention provides pharmaceutical compounds.
The pharmaceutical compounds provided by the invention are C11), C12) or C13) as described above.
Of the above pharmaceutical compounds, the pharmaceutical compounds have at least one of the uses of U1) -U3) below:
u1) is used for resisting virus;
U2) for the treatment and/or prophylaxis and/or adjuvant treatment of diseases caused by viral infections;
U3) is used to inhibit viral invasion into cells.
In U1) -U3) of the above pharmaceutical compounds, the virus may be an ebola virus (zaire type, sudan type, taisen type, bunyak type and/or leston type), or a marburg virus.
Above, the inhibiting viral entry into the cell may be inhibiting GPcl-mediated viral entry into the cell.
The pharmaceutical salts of the cyclic polypeptides of the invention include acetate (acetate), lactobionic acid (lactobionate), benzenesulfonate (benzenesulfonate), laurate (laurate), benzoate (benzoate), malate (malate), bicarbonate (bicarbonate), maleate (maleate), bisulfate (bisulfate), mandelate (mandelate), bitartrate (bitartrate), methanesulfonate (mesylate), borate (borate), bromomethane (methylbromide), bromide (bromomide), methyl nitrate (METHYLNITRATE), calcium edetate (calcium acetate), methylsulfate (methylsulfate), camphorsulfonic acid (camsylate), mucic acid (mucate), carbonate (carbonate), naphthalene sulfonate (napsylate), chloride (chloride), nitrate (nitrate), clavulanate (clavulanate), N-methylglucamine (N-methylglucamine), citrate (citrate), ammonium salt (ammonium salt), dihydrochloride (dihydrochloride), oleate (oleate), ethylenediamine tetraacetate (edetate), oxalate (oxalate), ethanedisulfonate (edisylate), pamoate (pamoate) (pamoate embonate), propionate laurate (estolate), palmitate (palmate), ethanesulfonate (esylate), pantothenate (pantothhenate), fumarate (fumarate), phosphate/diphosphate (phosphate/diphosphate), glucoheptonate (polygalacturonate), glucoheptonate (gluconate), salicylate (salicylate), glutamate (glutamate), stearate (stearate), paracetamol (glycollylarsanilate), sulfate (sulfate), hydroxybenzoate (hexylresorcinate), basic acetate (subacetate), seabar (hydramine), succinate (succinate), hydrobromide (hydrobromide), tanniate (tannate), hydrochloride (hydrochloride), tartrate (tartrate), hydroxynaphthoate (hydroxynaphthoate), 8-chlorotheophyllinate (teoclate), iodide (iodate), tosylate (tosylate), triethyliodide (triemide), lactate (lactate), valerate (valinate) and the like. Depending on the application, pharmaceutically acceptable salts may be formed from cations such as sodium (sodium), potassium (potassium), aluminum (aluminum), calcium (calcium), lithium (lithium), manganese (magnesium) and zinc (zinc), bismuth (bismuth), and the like, and bases such as ammonia, ethylenediamine (ethylenediamine), N-methyl-glutamine (N-methyl-glutamine), lysine (lysine), arginine (arginine), ornithine (ornithine), choline (choline), N '-dibenzylethylenediamine (N, N' -dibenzylethylene-diamine), chloroprocaine (chloroprocaine), diethanol ammonia (diethanol amine), procaine (procaine), diethylamine (DIETHYLAMINE), piperazine (piperazine), trimethylol-aminomethane (tris (hydroxymethyl) aminomethane), and tetramethylammonium hydroxide (tetramethylammonium hydroxide), and the like. These salts can be prepared by standard methods, for example by reaction of the free acid with an organic or inorganic base. In the presence of a basic group such as an amino group, an acidic salt such as hydrochloride (hydrobromide), hydrobromide (hydrobromide), acetate (acetate), pamoate (pamoate) and the like can be used as the dosage form; pharmaceutically acceptable esters such as acetate, maleate, chloromethyl trimethylacetate (pivaloyloxymethyl) and the like, as well as esters known in the literature for improving solubility and hydrolyzability, in the presence of an acidic group such as-COOH or an alcohol group, can be used as sustained release and prodrug formulations.
The cyclic polypeptide, the derivative or the pharmaceutically acceptable salt thereof, the polymer, the composition or the pharmaceutically acceptable compound provided by the invention can be used for treating EBOV and/or MARV infection. The lipopeptides or polypeptides, derivatives thereof, or pharmaceutically acceptable salts thereof, the multimers, the compositions or the pharmaceutically acceptable compounds provided herein may also be used for the prevention of EBOV and/or MARV infections, including pre-exposure or post-suspected exposure, such as blood transfusion, organ transplantation, fluid exchange, bite, accidental needle stick or intra-operative exposure to a patient's blood, and the like.
In practical applications, the cyclic polypeptide, derivative or pharmaceutically acceptable salt thereof, the multimer, the composition or the pharmaceutical compound of the invention may be administered directly to a patient as a medicament or after being mixed with a suitable carrier or excipient to treat and/or prevent EBOV and/or MARV infection. The carrier materials herein include, but are not limited to, water soluble carrier materials (e.g., polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.), poorly soluble carrier materials (e.g., ethylcellulose, cholesterol stearate, etc.), enteric carrier materials (e.g., cellulose acetate phthalate, carboxymethyl ethyl cellulose, etc.). Among them, preferred is a water-soluble carrier material. The materials can be prepared into various dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injection and the like. The suppository can be pessary, vaginal ring, ointment, cream or gel suitable for vaginal application. Can be common preparation, slow release preparation, controlled release preparation and various microparticle administration systems. For the purpose of shaping the unit dosage form into a tablet, various carriers known in the art can be widely used. Examples of carriers are, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; humectants and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, dextrose solution, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone, and the like; disintegrants such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid ester, sodium dodecyl sulfonate, methylcellulose, ethylcellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cocoa butter, hydrogenated oils and the like; absorption promoters such as quaternary ammonium salts, sodium lauryl sulfate, and the like; lubricants such as talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated into coated tablets, such as sugar coated tablets, film coated tablets, enteric coated tablets, or bilayer and multilayer tablets. For the purpose of formulating the unit dosage form into a pill, various carriers well known in the art can be widely used. Examples of carriers are, for example, diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oils, polyvinylpyrrolidone, gelucire, kaolin, talc, etc.; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, and the like; disintegrants such as agar powder, dry starch, alginate, sodium dodecyl sulfate, methylcellulose, ethylcellulose, etc. For preparing a unit dosage form into a suppository, various carriers well known in the art can be widely used. Examples of carriers include polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides, and the like. For preparing unit dosage forms into injectable preparations such as solutions, emulsions, lyophilized powders and suspensions, all diluents commonly used in the art, for example, water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxyisostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. may be used. In addition, in order to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose or glycerin may be added to the preparation for injection, and further, a conventional cosolvent, a buffer, a pH adjuster, and the like may be added. In addition, colorants, preservatives, flavors, flavoring agents, sweeteners, or other materials may also be added to the pharmaceutical formulation, if desired.
The preparation can be administrated by injection, including subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, intracisternal injection or infusion, etc.; administration via the luminal tract, such as rectally, vaginally, and sublingually; respiratory tract administration, such as via the nasal cavity; mucosal administration. The above route of administration is preferably injection, and the preferred route of injection is subcutaneous injection.
The dosage of the cyclic polypeptide of the present invention, its derivative, pharmaceutically acceptable salt, the multimer, the composition or the pharmaceutical compound to be administered depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight and individual response of the patient or animal, the specific active ingredient used, the route of administration and the number of administrations, etc. The above-mentioned doses may be administered in a single dosage form or divided into several, for example two, three or four dosage forms.
For any particular patient, the particular therapeutically effective dose level will depend on a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; age, weight, general health, sex and diet of the patient; the time of administration, route of administration and rate of excretion of the particular active ingredient employed; duration of treatment; a medicament for use in combination or simultaneously with the particular active ingredient employed; and similar factors well known in the medical arts. For example, it is common in the art to start doses of the active ingredient below the level required to obtain the desired therapeutic effect and to gradually increase the dose until the desired effect is obtained.
The cyclic polypeptide, the derivative thereof or the pharmaceutically acceptable salt thereof, the polymer, the composition or the pharmaceutical compound can be directly and independently used for treating and preventing EBOV and/or MARV infected persons, can also be used in combination with one or more anti-EBOV and/or MARV infected medicaments, can be used simultaneously or at intervals, and can achieve the aim of improving the overall treatment effect.
In the present invention, the antiviral activity may also be referred to as a viral inhibitory activity, and specifically may be a viral entry inhibition into cells.
Experiments prove that the cyclic polypeptide can specifically inhibit the ebola virus from entering cells. The cyclic polypeptide can specifically inhibit ebola virus from entering cells by combining with a target protein EBOV-GPcl, so as to achieve the effect of resisting EBOV infection. The cyclic polypeptide or the medicinal salt and the derivative thereof can be used as a novel EBOV entry inhibitor and can be applied to the development of vaccines or medicaments for resisting the EBOV.
Drawings
FIG. 1 shows that Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 are capable of specifically inhibiting EBOV-Zaire GP/HIV-luc recombinant viral activity. In FIG. 1, VSVG represents VSV-G/HIV-luc, ebola-GP represents EBOV-GP/HIV-luc, viral infection rate=1-inhibition rate.
FIG. 2 is a graph showing the effect of a polypeptide on 293T cell growth as demonstrated by cell growth experiments.
FIG. 3 shows that Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 have good dose dependence on the inhibition of EBOV-Zaire GP/HIV-luc recombinant virus.
FIG. 4 shows the effect of polypeptide Pep-3.3 on the entry phase of virus.
FIG. 5 is a graph showing the kinetic binding curves of different concentrations of the polypeptide Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 to the target protein GPcl measured in vitro by biological membrane layer optical interferometry. In the figure, arrows show the concentrations of the respective samples.
Detailed Description
The invention is realized by the following technical scheme:
First, a structure-based polypeptide drug design was performed using the C-terminal loop structure (amino acid sequence DDFFVY) of the NPC1 domain as a template. To improve the stability of the polypeptide, it is protected from phosphatase, and a cysteine is introduced at each end of the amino acid sequence, thereby introducing a disulfide bond. Then, the stability of the polypeptide is further improved by amidation modification of the carbon end and acetylation modification of the nitrogen end. The polypeptide structure is Ac-cyclo (CDDFFVYC) -NH 2. In order to improve the binding capacity of the polypeptide and the target protein EBOV-GPcl, the structure of the polypeptide is further optimized by constructing single-point, double-point and three-point amino acid mutations, so as to obtain the optimal combination sequence of the polypeptide. Then, the designed polypeptide was inoculated into the target protein GPcl, and a polypeptide having a superior free energy (Table 1) was selected for solid phase synthesis.
EBOV is classified as a dangerous quaternary virus, so that the polypeptides are evaluated for biological activity at the in vitro level using a safe and effective research approach, the pseudovirus technique. The replication-defective pseudovirus EBOV-GP/HIV-luc is prepared by wrapping HIV cores with GP proteins of the Tie-Emi type EBOV with the highest toxicity, and the antiviral activity of the sample is judged by a fluorescent reporter gene detection technology. Meanwhile, the specificity of the polypeptides was analyzed using a VSVG/HIV-luc recombinant virus model. After removal of cytotoxicity, the mechanism of action of the polypeptides was further verified using a drug action time point experiment. Finally, the binding capacity of the polypeptide and the target protein GPcl is measured in vitro by utilizing a biological film layer optical interference technology based on an optical fiber biosensor, and the targeting of the polypeptide is verified.
All polypeptides in Table 1 were modified by amino-terminal homoacetylation (Ac-), carboxy-terminal homoamidation (-NH 2). "Cyclo" means that the amino acid sequence in brackets forms a cyclic polypeptide with the amino acid residue at position 1 and the amino acid residue at position 1 last. In Pep-1, the amino acid sequence in brackets is connected with the amino acid residue at the last 1 position through an amide bond to form a cyclic polypeptide; in Pep-3, pep-3.1, pep-3.2, pep-3.3, pep-3.6, pep-3.7 and Pep-3.10, the amino acid sequence in brackets is linked with the amino acid residue at the last 1 position through disulfide bond formation to form a cyclic polypeptide.
TABLE 1 sequence structure of polypeptides
Name of the name | Sequence structure |
Pep-1 | Ac-cyclo(DDFFVY)-NH2 |
Pep-2 | Ac-DDFFVY-NH2 |
Pep-3 | Ac-cyclo(CDDFFVYC)-NH2 |
Pep-3.1 | Ac-cyclo(CHYFFVYC)-NH2 |
Pep-3.2 | Ac-cyclo(CDYFFWYC)-NH2 |
Pep-3.3 | Ac-cyclo(CEYFFWYC)-NH2 |
Pep-3.6 | Ac-cyclo(CDRFFVYC)-NH2 |
Pep-3.7 | Ac-cyclo(CDYFFRYC)-NH2 |
Pep-3.10 | Ac-cyclo(CYYFFVHC)-NH2 |
The polypeptides of table 1 were all synthesized by beijing Saint gene technologies, inc, with purity >98%. The specific acquisition means is the prior art, and the present invention is not particularly limited thereto.
The following detailed description of the invention is provided in connection with the accompanying drawings that illustrate the invention and are not intended to limit the scope of the invention. Although the following describes the antiviral mechanism of the present invention by taking zaire EBVO as an example, the scope of protection of the use of the polypeptide is not limited to EBOV. Any virus suitable for the above antiviral mechanism is within the scope of the present invention, and may be, for example, other four subtypes of EBOV, MARV, etc.
In addition, it should be noted that the various materials and reagents used in the following examples are those commonly used in the art and are commercially available in general terms unless otherwise indicated; the methods used are conventional methods known to those skilled in the art or according to the conditions recommended by the manufacturer.
Example 1, EBOV entry inhibitor screening model verifies that Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 are capable of specifically inhibiting EBOV activity.
The recombinant virus (EBOV-GP/HIV-luc) was prepared by coexpression of the GP of Zaire-EBOV with the HIV core plasmid (pNL 4-3. Luc) using a cell-level recombinant virus technique, and the antiviral activity of the polypeptides was evaluated using a high throughput screening model of EBOV entry inhibitors targeting the GP protein. The method comprises the following specific steps:
293T cells were cultured, and after the cells were grown in the flask, the old medium was discarded and digested with a digest containing 0.25% pancreatin and 0.02% EDTA. After the cells were rounded, the digests were discarded, and immediately high-sugar DMEM medium (GIBICO) containing 10% fbs (purchased from GIBCO) was added, the bottom was gently blown with a pipette, the cells were completely detached from the bottom and dispersed as a single cell suspension. After counting, the cell concentration was adjusted to 2.2X10 5 cells/mL with medium and plated in 6-well plates at 2 mL/well. After 24h (cell abundance approximately 70%) transfection, plasmid dose: 2 mu g pZEBOV-GP and 3. Mu.g of HIV-luc plasmid pNL4-3.Luc. R-E-carrying a luciferase reporter gene, the transfection reagent was Lipofectamine2000 (Invitrogen company), and transfection was performed according to the instructions to generate Ebola pseudotype virus, which was designated EBOV-GP/HIV-luc or EBOV-Zaire GP/HIV-luc. Supernatants containing pseudotyped virus were collected 48 hours post-transfection, pooled, clarified from floating cells and cell debris by low-speed centrifugation, and filtered through a 0.45 μm pore size filter. The pseudo-viral particles were quantified by measuring virus-related HIV p24 levels using an ELISA assay.
Wherein pZEBOV-GP is a recombinant expression plasmid of Glycoprotein (GP) expressing Zaire-EBOV obtained by inserting the 5900-8305 th position of the Zaire ebolavirus isolate H.sapiens-wt/GIN/2014/Makona-Gueckedou-C07 GP gene (GenBank Accession No. KJ660347 (Update Date Dec 18, 2014: 25 PM) into the vector pcDNA3.1 (+).
EBOV-GP/HIV-luc pseudovirions were incubated with 293T cells in 96-well plates. After 48 hours, cells were collected and lysed to measure firefly luciferase activity. The value of luciferase activity represents a viral infection.
The polypeptides of Table 1 were dissolved in DMSO and mixed with EBOV-GP/HIV-luc pseudoviruses, respectively, and added to 293T cells to give a polypeptide content of 10. Mu.M. After 48 hours, 293T cells were lysed and the inhibition of the virus by the polypeptide was assessed by measuring luciferase activity. Solvent DMSO was used as a blank (DMSO) and EBOV entry inhibitor tetrandrine (TET) and HIV-1 reverse transcriptase inhibitor Efavirenz (EFV) were introduced simultaneously as controls. The tetrandrine and the efavirenz are respectively dissolved by DMSO and then respectively mixed with EBOV-GP/HIV-luc pseudovirus to be added into 293T cells, and the content of the tetrandrine and the efavirenz is 1 mu M. After 48 hours, 293T cells were lysed and the inhibition of the virus by the polypeptide was assessed by measuring luciferase activity.
Most of the currently known EBOV inhibitors are broad-spectrum antiviral drugs, and in order to find a narrow-spectrum inhibitor against EBOV, a specific analysis of the screened active polypeptide is required. Since vesicular stomatitis virus coat glycoprotein (vesicular stomatitis virus glycoprotein, VSVG) acts similarly to EBOV-GPcl, and plays an important role in the recognition of viruses and receptors, the screened active polypeptides were specifically analyzed using pseudoviruses expressing VSV-GP. After removal of the cytotoxic factors, the inhibitory activity of the active polypeptide against VSV-G/HIV-luc pseudovirus was also detected using luciferase-associated preparation, as described above. If the polypeptide has an obvious inhibition effect on the virus entry mediated by the EBOV-GPcl, but has no inhibition or low inhibition rate on VSV, the polypeptide is proved to have specificity on the EBOV.
As shown in FIG. 1, the inhibition rate of Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 on EBOV-GP/HIV-luc pseudoviruses is higher than 80%, and the inhibition rate on VSV-G/HIV-luc pseudoviruses at the same concentration is lower than 50%. This suggests that Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 have specific inhibitory effects on the EBOV-GP/HIV-luc pseudoviruses. Among them, pep-3.3 has the most remarkable specific inhibition effect. The EBOV entry inhibitor tetrandrine (TET) as a positive control has a similar selective inhibition to the active polypeptide, whereas the HIV-1 reverse transcriptase inhibitor Efavirenz (EFV) has an inhibitory effect on both pseudoviruses.
Wherein, the preparation method of pseudovirus VSV-G/HIV-luc expressing VSV-GP is different from the preparation method of EBOV-GP/HIV-luc only in that pZEBOV-GP in the preparation method of EBOV-GP/HIV-luc is replaced by pVSV-GP, and other operations are identical. pVSV-GP is a recombinant expression plasmid expressing vesicular stomatitis virus coat glycoprotein, which is obtained by inserting the 14 th to 1567 th positions of the vesicular stomatitis virus coat glycoprotein GP gene (GenBank Accession No. V01114 (Update Date Feb 4,2011)) into the vector pcDNA3.1+.
The antiviral activity of examples 2, pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 was independent of their cytotoxicity.
To exclude non-specific differences due to polypeptide toxicity, the effect of the polypeptide on 293T cell growth was assessed using a cell counting kit-8 (ell Counting Kit-8, CCK-8).
The CCK-8 kit is a kit for detecting cell proliferation, cell survival and cytotoxicity, is a widely applied rapid high-sensitivity detection kit based on WST-8 (water-soluble tetrazolium salt, chemical name: 2- (2-methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2, 4-disulfophenyl) -2H-tetrazolium monosodium salt), is an alternative method of MTT method, adopts water-soluble tetrazolium salt-WST-8 in the kit, and can be reduced by some dehydrogenases in mitochondria to generate orange formazan in the presence of an electronic coupling reagent. The more and the faster the cell proliferation, the darker the color; the greater the cytotoxicity, the lighter the color. For the same cells, the shade of color and the number of cells are in good linear relationship. The method comprises the following specific steps:
293T cells were cultured in 96-well plates and incubated with the polypeptides of Table 1 (dissolved in DMSO) in a medium of 25. Mu.M. After 48 hours, the cell supernatant was changed to a cell culture medium containing 10% CCK-8 reagent and the cells were continuously cultured in a 5% CO 2 incubator at 37℃for 1 hour. The Optical Density (OD) values per well at 450nm were recorded on a microplate reader (Thermo, varioskan Flash). The solvent DMSO was used as a blank (DMSO), tetrandrine (TET) was used as a control, and the content of tetrandrine in the medium was 3.125 μm (tetrandrine was not cytotoxic at this concentration, which was used as a positive control).
As shown in FIG. 2, at a concentration of 25. Mu.M (well above the measured IC 50 value), the polypeptide had no significant effect on cell activity. Thus, it is demonstrated that the antiviral activity of the polypeptide is independent of its cytotoxicity.
Example 3, pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 have good dose dependence on the inhibition of EBOV.
With reference to the procedure in example 1, different concentrations of Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 of Table 1 were dissolved in DMSO and mixed with EBOV-GP/HIV-luc pseudoviruses, respectively, to 293T cells. After 48 hours, 293T cells were lysed and peptides were assessed for anti-EBOV activity by measuring luciferase activity. Solvent DMSO was used as a control (DMSO), and luciferase activity of the control was taken as 100% of cell viability. As can be seen from FIG. 3, pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 significantly inhibited the EBOV-GP/HIV-luc pseudoviral activity in a dose-dependent manner.
Example 4 determination of the entry phase of Pep-3.3 action on virus by drug action time point experiments.
The specific inhibition of the EBOV-GP/HIV-luc pseudoviruses by the polypeptides Pep-3.1, pep-3.2, pep-3.3 and Pep-3.10 suggests that they may act as EBVO entry inhibitors. To verify this, the stage of action of the polypeptide in the viral infection cycle was studied by a Time of day (TOA) experiment. Since in example 1 Pep-3.3 has the strongest specific inhibitory effect on the EBOV-GP/HIV-luc pseudovirus, the mechanism of action of Pep-3.3 was mainly studied. The method comprises the following specific steps:
The day before infection, 293T cells were seeded into 96-well plates at a cell number of 6X 10 4/well and 50. Mu.L of the infected cells of EBOV-GP/HIV-luc of example 1 were added, respectively. Pep-3.3 (dissolved in DMSO at 1×10 -5mol·L-1 in medium) of table 1, as an EBOV entry inhibitor tetrandrine (TET) (dissolved in DMSO at 1×10 -7mol·L-1 in medium), non-nucleoside reverse transcriptase inhibitor efavirenz (efavirenz, EFV) (dissolved in DMSO at 1×10 -9mol·L-1 in medium) as a control, and as a solvent control, was added at 0, 2,4, 6, 8, 10, 12, 14 and 16h time points during infection (-1 hour), during infection (0 hour), and after infection; 48h after infection, the luciferase activity of the reporter gene is detected to reflect the replication level of the recombinant virus.
The action link of the medicine can be primarily judged by measuring the failure time of the medicine in single infection of the EBOV. As shown in FIG. 4, pep-3.3 showed very strong inhibition early in viral entry, and no inhibition of viral infection after 4h (viral completed adsorption process). This is consistent with the time of action of EBOV into the inhibitor tetrandrine. The non-nucleoside reverse transcriptase inhibitor efavirenz still has an inhibiting effect on viruses at 6 hours. These results indicate that Pep-3.3 functions after the virus binds to the host and before membrane fusion of the virus to the host occurs.
Example 5 in vitro determination of binding Capacity of polypeptide to target protein GPc l Using biological Membrane layer optical interference technique
The surface glycoprotein GP of the ebola virus envelope is subjected to enzyme digestion treatment of host protease Cathepsin in endocytosis to become activated glycoprotein GPcl, and a receptor binding site is exposed. To verify that the polypeptide specifically inhibited viral entry by binding to the target protein GPcl, the binding capacity of the polypeptide to the target protein GPcl was determined in vitro using a fiber optic biosensor-based biofilm layer optical interference (BioLayer Interferometry, BLI) technique. The BLI technique is capable of tracking interactions between biomolecules in real time and is an ideal choice for studying interactions of proteins and other biomolecules. The method comprises the following specific steps:
The experiment was performed using a Ni-NTA (NTA) biosensor, using an Octet RED96 (ForteBio, inc.) instrument. The experiment is mainly carried out by the following steps: 1) Detecting a base line, immersing the NAT sensor in a buffer solution, and standing for 120s to achieve balance; 2) Incubating the protein onto the sensor, moving the sensor probe into a solution (50 mug/ml) of the purified GPcl protein with His tag, standing for 600s, and fixing the protein on the NTA sensor; 3) The sensor is moved into the buffer solution for standing for 120s to reach balance after the second detection baseline; 4) Measuring the Kon value in combination with moving the sensor into the polypeptide solution and standing for 60 s; 5) Dissociation the sensor was moved into buffer solution and allowed to stand for 60s to obtain Koff values. Four different concentrations of polypeptide were used in this process to obtain the final kinetic profile. Experimental data were analyzed using ForteBio data analysis software DATA ANALYSIS 9.0.0. Dissociation rate constant kd=k off/Kon.
The abscissa in fig. 5 represents the reaction time in seconds. The ordinate is GPcl the signal intensity of the interaction with the polypeptide in nm. The results showed that Pep-3.1, pep-3.2, pep-3.3, and Pep-3.10 of Table 1 were each capable of binding to GPcl proteins, and that the fitted dissociation rate constants KD were 119.8. Mu.M, 97.4. Mu.M, 69.7. Mu.M, and 31. Mu.M, respectively.
Sequence listing
<110> Institute of medical biotechnology of the national academy of medical science
<120> Cyclic Polypeptides or pharmaceutically acceptable salts thereof for use against Ebola Virus
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 8
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 1
Cys Glu Tyr Phe Phe Trp Tyr Cys
1 5
<210> 2
<211> 8
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 2
Cys Asp Tyr Phe Phe Trp Tyr Cys
1 5
<210> 3
<211> 8
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 3
Cys His Tyr Phe Phe Val Tyr Cys
1 5
<210> 4
<211> 8
<212> PRT
<213> Artificial sequence (ARTIFICIAL SEQUENCE)
<400> 4
Cys Tyr Tyr Phe Phe Val His Cys
1 5
Claims (5)
1. A cyclic polypeptide or a pharmaceutically acceptable salt thereof, characterized in that: the cyclic polypeptide is Pep-3.1 or Pep-3.10; the amino acid sequence of the Pep-3.1 is SEQ ID No.3 in a sequence table, and the amino acid sequence of the Pep-3.10 is SEQ ID No.4 in the sequence table.
2. A derivative of the cyclic polypeptide of claim 1, which is a linker obtained by linking an amino-terminal protecting group at the amino terminus of the cyclic polypeptide and/or a carboxy-terminal protecting group at the carboxy terminus of the cyclic polypeptide.
Multimers of PM1 or PM 2:
PM1, a multimer formed from the cyclic polypeptide of claim 1 or a pharmaceutically acceptable salt thereof;
PM2, a multimer formed from the derivative of claim 2.
4. A composition comprising C1) and C2): c1 C11), C12) or/and C13); the C11) is the cyclic polypeptide of claim 1 or a pharmaceutically acceptable salt thereof; the C12) is a derivative according to claim 2; the C13) is the multimer of claim 3;
C2 Pharmaceutically acceptable carriers or excipients;
The composition has at least one of the following functions F1) -F3):
F1 Antiviral;
F2 Treatment and/or prevention and/or adjuvant therapy of diseases caused by viral infections;
F3 Inhibiting viral invasion into cells;
In F1) -F3), the virus is Ebola virus.
Use of C11), C12), C13) or/and C14) for the preparation of at least one of the products E1) to E3):
the C11) is the cyclic polypeptide of claim 1 or a pharmaceutically acceptable salt thereof; the C12) is a derivative according to claim 2; the C13) is the multimer of claim 3;
the C14) is the composition of claim 4;
the E1) is an antiviral product;
The E2) is a product for treating and/or preventing and/or assisting in treating diseases caused by virus infection;
Said E3) is a product that inhibits viral entry into cells;
The E1) -E3), the virus is Ebola virus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111413917.0A CN113999284B (en) | 2018-01-25 | 2018-01-30 | Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018100728036 | 2018-01-25 | ||
CN201810072803 | 2018-01-25 | ||
CN201810087839.1A CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
CN202111413917.0A CN113999284B (en) | 2018-01-25 | 2018-01-30 | Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810087839.1A Division CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113999284A CN113999284A (en) | 2022-02-01 |
CN113999284B true CN113999284B (en) | 2024-05-17 |
Family
ID=62890075
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810087839.1A Active CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
CN202111413917.0A Active CN113999284B (en) | 2018-01-25 | 2018-01-30 | Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus |
CN202010460222.7A Active CN111574588B (en) | 2018-01-25 | 2018-01-30 | Polypeptide and application thereof in resisting Ebola virus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810087839.1A Active CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010460222.7A Active CN111574588B (en) | 2018-01-25 | 2018-01-30 | Polypeptide and application thereof in resisting Ebola virus |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN108314706B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115974973A (en) * | 2021-10-14 | 2023-04-18 | 浙江大学 | Polypeptide for inhibiting TRPM8 and application thereof |
CN114028453B (en) * | 2021-12-07 | 2023-05-30 | 北京中医药大学 | Broad-spectrum antiviral medicine, its medicinal composition and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105063044A (en) * | 2014-10-17 | 2015-11-18 | 苏州圣诺生物医药技术有限公司 | Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof |
CN105663123A (en) * | 2016-03-24 | 2016-06-15 | 中国科学院微生物研究所 | Application of tebufenpyrad structure containing compound to preparation of Ebola virus infection resisting medicines |
CN105726525A (en) * | 2016-03-24 | 2016-07-06 | 中国科学院微生物研究所 | Application of compound containing Merochlorin A structure in preparation of medicines of resisting ebola virus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002324753A1 (en) * | 2001-08-20 | 2003-07-09 | Myriad Genetics, Inc | Composition and method for treating viral infection |
GB0526120D0 (en) * | 2005-12-22 | 2006-02-01 | Novabiotics Ltd | Therapeutic peptides |
US9101635B2 (en) * | 2009-07-10 | 2015-08-11 | Microbiotix, Inc. | Inhibitors of filovirus entry into host cells |
US10706955B2 (en) * | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CN109700823B (en) * | 2014-08-18 | 2021-07-06 | 中国医学科学院药物研究所 | Application of telithromycin in resisting ebola virus infection |
CN106636014A (en) * | 2015-10-28 | 2017-05-10 | 中国科学院上海巴斯德研究所 | Novel in-vitro and in-vivo infection model based on Ebola virus-like particles |
CN107033242B (en) * | 2017-04-16 | 2019-11-05 | 中国人民解放军军事医学科学院生物工程研究所 | A kind of monoclonal antibody and application of the anti-Ebola virus envelope glycoprotein of source of people |
-
2018
- 2018-01-30 CN CN201810087839.1A patent/CN108314706B/en active Active
- 2018-01-30 CN CN202111413917.0A patent/CN113999284B/en active Active
- 2018-01-30 CN CN202010460222.7A patent/CN111574588B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105063044A (en) * | 2014-10-17 | 2015-11-18 | 苏州圣诺生物医药技术有限公司 | Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof |
CN105663123A (en) * | 2016-03-24 | 2016-06-15 | 中国科学院微生物研究所 | Application of tebufenpyrad structure containing compound to preparation of Ebola virus infection resisting medicines |
CN105726525A (en) * | 2016-03-24 | 2016-07-06 | 中国科学院微生物研究所 | Application of compound containing Merochlorin A structure in preparation of medicines of resisting ebola virus infection |
Also Published As
Publication number | Publication date |
---|---|
CN111574588A (en) | 2020-08-25 |
CN108314706A (en) | 2018-07-24 |
CN111574588B (en) | 2021-11-09 |
CN108314706B (en) | 2020-06-16 |
CN113999284A (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020024719A1 (en) | Use of berbamine dihydrochloride in preparation of ebola virus inhibitor | |
CN111643656B (en) | Broad-spectrum coronavirus membrane fusion inhibitor and application thereof in resisting AIDS virus | |
CN114736272B (en) | Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and application | |
ES2381631T3 (en) | HIV fusion inhibitor peptides with improved biological properties | |
US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
AU2017410525B2 (en) | Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof | |
WO2022262820A1 (en) | Group of imb-c5 series compounds having anti-coronavirus activity and application thereof | |
CN113999284B (en) | Cyclic polypeptides or pharmaceutically acceptable salts thereof for use against ebola virus | |
CN115746148B (en) | Proteins with coronavirus RBD and membrane fusion inhibiting polypeptides and their use as coronavirus inhibitors | |
CN101687911A (en) | Cysteic acid derivatives of anti-viral peptides | |
CN115724919A (en) | Novel membrane fusion inhibitor for strongly inhibiting AIDS virus and drug-resistant strains thereof and pharmaceutical application thereof | |
CN102816215A (en) | Smallish polypeptide capable of inhibiting HIV and medicinal use thereof | |
KR20100080812A (en) | Methods of synthesis for therapeuthic anti-hiv peptides | |
CN116444644A (en) | Broad-spectrum virus membrane fusion inhibitor and preparation method and application thereof | |
CN113855694B (en) | Use of adenosine kinase inhibitors in preparation of anti-coronavirus preparations | |
AU2017415108A1 (en) | Peptides and uses therefor as antiviral agents | |
WO2012076822A1 (en) | Peptides and antiviral drug | |
WO2024192623A1 (en) | Broad-spectrum viral membrane fusion inhibitor, and preparation method therefor and use thereof | |
CN118684745A (en) | Anti-HIV-1 polypeptide, derivative and application thereof | |
WO2014022947A1 (en) | Short polypeptide inhibiting hiv and pharmacal use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |